Viatris Inc
Change company Symbol lookup
Select an option...
VTRS Viatris Inc
SHOO Steven Madden Ltd
SEGI Sycamore Entertainment Group Inc
KVLQF ValOre Metals Corp
TLLZF Gold Line Resources Ltd
RIGMF Ridgestone Mining Inc
FLURF FluroTech Ltd
NICLF Class 1 Nickel and Technologies Ltd
CAVVF CAVU Energy Metals Corp
MEXGF Mexican Gold Mining Corp
Go

Health Care : Pharmaceuticals | Mid Cap Value
Company profile

Viatris Inc. is a global healthcare company. The Company has four segments: Developed Markets, Greater China, JANZ and Emerging Markets. Developed Markets segment comprises its operations primarily in North America and Europe. Greater China segment includes its operations in China, Taiwan and Hong Kong. JANZ segment reflects its operations in Japan, Australia and New Zealand. Emerging Markets segment encompasses its presence in approximately 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as its anti-retroviral franchise. Its portfolio comprises approximately 1,400 approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands, generics, complex generics, and biosimilars. It operates approximately 40 manufacturing sites worldwide, which produces oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.

Closing Price
$12.25
Day's Change
0.24 (2.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
12.25
Day's Low
11.97
Volume
(Above Average)
Volume:
12,015,700

10-day average volume:
10,629,021
12,015,700

Display:

Providers:

UpdateCancel
6 providers
May 20, 2022
Viatris to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference

Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today announced the company will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference at the Terranea Resort in Rancho Palos Verdes, CA on Tuesday, June 14, 2022...(PR Newswire)

May 16, 2022
Viatris Publishes Sustainability Report Highlighting 2021 Progress, Achievements and Goals

Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today published its 2021 Sustainability Report, outlining the company's 2021 achievements and progress across key areas including Access and Global Health, Employees, Environmental...(PR Newswire)

May 09, 2022
Thinking about buying stock in Palantir Technologies, Society Pass, Vinco Ventures, Plug Power, or Viatris?

InvestorsObserver issues critical PriceWatch Alerts for PLTR, SOPA, BBIG, PLUG, and VTRS. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

Viatris Reports Strong First-Quarter 2022 Results

-- First-Quarter 2022 Results Reflect Strong Operational Start to the Year -- Total Revenues Were $4.19 billion -- U.S. GAAP Net Earnings Were $399.2 million -- Adjusted EBITDA was $1.59 billion -- U.S. GAAP Net Cash Provided by Operating Activities...(PR Newswire)

April 08, 2022
Viatris Inc. to Release First Quarter 2022 Financial Results on May 9, 2022

Viatris Inc. (NASDAQ: VTRS) plans to release its first quarter 2022 financial results on Monday, May 9, before the open of the U.S. financial markets. Chief Executive Officer Michael Goettler, President Rajiv Malik, and Chief Financial Officer...(PR Newswire)

March 31, 2022
Mapi Pharma to Present Posters on GA Depot for Treating Relapsing Forms of Multiple Sclerosis (MS) and Primary Progressive Forms of Multiple Sclerosis at the American Academy of Neurology (AAN) 2022 Annual Meeting

Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable solutions mainly for neurological indications, announced today that two posters featuring...(Globe Newswire)

March 30, 2022
Mapi Pharma Receives U.S. Patent Covering Methods of Suppressing or Alleviating Primary or Secondary Progressive Multiple Sclerosis with a Sustained Release Glatiramer Acetate Depot

Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable solutions mainly for neurological indications, announced today that the company has been...(Globe Newswire)

March 17, 2022
Viatris Defeats Biogen's Attempt to Revive Tecfidera Patent

Federal Circuit Refuses to Reconsider Decision Invalidating Biogen's Patent Covering its Multiple Sclerosis Product Tecfidera(R) Viatris Inc. (NASDAQ: VTRS) today announced that it is pleased with the decision by the United States Court of Appeals...(PR Newswire)

March 16, 2022
Viatris Inc. Announces Receipt of the First FDA Approval for Generic Version of Symbicort(R) Inhalation Aerosol, Breyna(TM) (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), in Partnership with Kindeva

Approval continues track record of successful firsts in developing complex generic medicines to help increase patient access Viatris Inc. (NASDAQ: VTRS) and Kindeva Drug Delivery L.P. today announced that, Mylan Pharmaceuticals Inc., a Viatris...(PR Newswire)

March 01, 2022
Viatris to Participate in Upcoming Investor Conferences

Viatris Inc. (NASDAQ: VTRS) today announced the company will participate in the following investor conferences: -- Chief Executive Officer Michael Goettler and Chief Financial Officer Sanjeev Narula will participate in a fireside chat at the Raymond...(PR Newswire)

February 28, 2022
Thinking about buying stock in Mullen Automotive, Camber Energy, Palantir Technologies, American Airlines, or Viatris?

InvestorsObserver issues critical PriceWatch Alerts for MULN, CEI, PLTR, AAL, and VTRS. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

Biocon Biologics to Acquire Viatris' Biosimilars Assets for up to USD 3.335 billion in Stock and Cash

Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523) (NSE: BIOCON), has entered into a definitive agreement with its partner Viatris Inc. (NASDAQ: VTRS). Accordingly, Biocon Biologics Ltd. (BBL) will acquire Viatris' biosimilars...(PR Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.